​

Immunome Stock (NASDAQ:IMNM)

ForecastRevenueOwnershipFinancialsChart
Immunome by TradingView

Previous Close

$18.16

52W Range

$7.96 - $27.65

50D Avg

$21.90

200D Avg

$19.13

Market Cap

$1.76B

Avg Vol (3M)

$1.22M

Beta

2.07

Div Yield

-

IMNM Company Profile

Immunome, Inc. functions as a biopharmaceutical company dedicated to the discovery and advancement of antibody-based therapies for both cancer and infectious illnesses. A pivotal project in its oncology portfolio is IMM-ONC-01, which is engineered to target the IL-38 immune checkpoint – a protein originating from tumors that enables cancer cells to bypass the body's immune surveillance. Additionally, the company is developing IMM-BCP-01, an experimental antibody cocktail designed for the management of SARS-CoV-2 infections and COVID-19. This enterprise was founded in 2006 and its principal operations are based in Exton, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

131

IPO Date

Oct 02, 2020

Website

IMNM Performance

IMNM Financial Summary

Dec 25Dec 24Dec 23
Revenue$6.94M$9.04M$14.02M
Operating Income$-224.11M$-305.80M$-109.53M
Net Income$-212.39M$-292.96M$-106.81M
EBITDA$-224.11M$-151.35M$-28.00M
Basic EPS$-2.43$-5.00$-5.38
Diluted EPS$-2.43$-5.00$-5.38

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
PHVSPharvaris N.V.
MAZEMaze Therapeutics, Inc.
UPBUpstream Bio, Inc.
SYRESpyre Therapeutics, Inc.
ABCLAbCellera Biologics Inc.
BHVNBiohaven Ltd.
CLDXCelldex Therapeutics, Inc.
NTLAIntellia Therapeutics, Inc.
VERAVera Therapeutics, Inc.
ZBIOZenas BioPharma, Inc.